CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Dermira, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Dermira, Inc.
275 Middlefield Road
Suite 150
Phone: (650) 421-7200p:650 421-7200 Menlo Park, CA  94025-4008  United States Fax: (302) 674-5266f:302 674-5266

This company was Merged or Acquired on 2/20/2020.
This company ceased filing statements with the SEC on 3/2/2020.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Dermira, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis and atopic dermatitis. The Company’s portfolio consists of QBREXZA and Lebrikizumab. QBREXZA is a once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients. QBREXZA is applied directly to the skin and is designed to block underarm sweat production by inhibiting sweat gland activation. Lebrikizumab is an injectable, humanized monoclonal antibody targeting interleukin 13 (IL-13) that the Company is developing for the treatment of moderate-to-severe atopic dermatitis.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201912/31/2018YesYes-YesYes

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Chief Executive Officer, Co-Founder Thomas G.Wiggans 67 4/1/2014 8/1/2010
Co-Founder, Chief Development Officer Luis C.Pena 56 2/1/2016 1/1/2010
Chief Financial Officer Andrew L.Guggenhime 49 5/3/2018 4/1/2014
9 additional Officers and Directors records available in full report.

Business Names
Business Name
DERM
Dermira Canada, Inc.

General Information
Number of Employees: 333 (As of 12/31/2018)
Outstanding Shares: 54,521,180 (As of 10/31/2019)
Shareholders: 16
Stock Exchange: NASD
Federal Tax Id: 273267680
Fax Number: (302) 674-5266
Email Address: info@dermira.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023